Vericiguat's Effects on Acute Coronary Syndrome Patients with Diminished Ejection Fraction: Insights from the EVE-ACSrEF Trial
By
Xinying Shi
Anran Zhao
Yi Ding
Lingfeng Gu
Tongtong Yang
Hao Wang
Qiming Wang
Sibo Wang
Liansheng Wang
February 21, 2026
Clinical Scorecard: Vericiguat's Effects on Acute Coronary Syndrome Patients with Diminished Ejection Fraction: Insights from the EVE-ACSrEF Trial
At a Glance
Category Detail
Condition Acute Coronary Syndrome (ACS) with Heart Failure and Reduced Ejection Fraction (HFrEF) Key Mechanisms Involves the NO-sGC-cGMP signaling pathway and atherothrombosis due to plaque rupture. Target Population Patients with ACS complicated by HFrEF (LVEF < 45%) Care Setting Hospitalization and outpatient follow-up
Key Highlights
Vericiguat is a novel oral soluble guanylate cyclase stimulator. The study evaluates vericiguat's efficacy in reducing cardiovascular death and hospitalization for heart failure. Inclusion criteria include symptomatic heart failure classified as NYHA class II-IV. The study aims to assess the impact on cardiac function and quality of life. A total of 149 patients were included in the analysis. Guideline-Based Recommendations
Diagnosis
Meet current guideline diagnostic criteria for ACS. Echocardiographic confirmation of LVEF < 45%. Management
Standard GDMT includes beta-blockers, ACEI/ARB/ARNI, SGLT2i, and MRA. Dual antiplatelet therapy (DAPT) recommended within 12 months post-ACS. Monitoring & Follow-up
Regular monitoring of medication usage, adverse events, and endpoint events. Risks
Elevated risk of hospitalization for heart failure and major adverse cardiovascular events. Patient & Prescribing Data
Patients aged 18-90 with ACS and HFrEF.
Vericiguat initiated during hospitalization and continued long-term post-discharge.
Clinical Best Practices
Adhere to evidence-based stepwise optimization protocols for GDMT. Monitor hemodynamic assessments and adjust vericiguat dosage based on clinical symptoms. Related Resources & Content
